Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA) Downgraded by Wall Street Zen to Sell

Key Points

• Wall Street Zen downgraded DMRA from “Hold” to “Sell,” although broader analyst sentiment remains positive, with a consensus “Buy” rating and an average price target of $46.50.
• DMRA opened at $20.65, with a market capitalization of approximately $1.27 billion. The stock has traded between $3.64 and $38.33 over the past year and remains unprofitable, with a price-to-earnings ratio of -6.13.
• CEO Jennifer Jarrett purchased 12,500 shares for about $252,875, increasing her stake by 2.5%; institutional investors and hedge funds own approximately 14.2% of the company.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) was downgraded by stock analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research report issued on Saturday, Wall Street Zen reports.

A number of other research analysts also recently commented on DMRA. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Damora Therapeutics, Inc. Common Stock in a research note on Monday, September 14th. TD Cowen raised shares of Damora Therapeutics, Inc. Common Stock to a "strong-buy" rating in a research report on Monday, August 24th. Guggenheim boosted their target price on shares of Damora Therapeutics, Inc. Common Stock from $40.00 to $60.00 and gave the company a "buy" rating in a report on Friday, September 25th. HC Wainwright restated a "buy" rating and issued a $45.00 target price on shares of Damora Therapeutics, Inc. Common Stock in a report on Tuesday, July 21st. Finally, Jefferies Financial Group began coverage on shares of Damora Therapeutics, Inc. Common Stock in a research report on Monday, July 27th. They set a "buy" rating and a $50.00 price target for the company. Three investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of "Buy" and a consensus target price of $46.50.

Damora Therapeutics, Inc. Common Stock Stock Up 2.1%

DMRA stock opened at $20.65 on Friday. The stock has a market capitalization of $1.27 billion, a price-to-earnings ratio of -6.13 and a beta of 1.43. Damora Therapeutics, Inc. Common Stock has a 52-week low of $3.64 and a 52-week high of $38.33. The stock's fifty day simple moving average is $27.42 and its 200-day simple moving average is $26.07.

Damora Therapeutics, Inc. Common Stock (NASDAQ:DMRA - Get Free Report) last released its earnings results on Monday, August 10th. The company reported ($0.39) EPS for the quarter, beating the consensus estimate of ($0.45) by $0.06. As a group, analysts anticipate that Damora Therapeutics, Inc. Common Stock will post -2.06 earnings per share for the current fiscal year.

Insider Activity at Damora Therapeutics, Inc. Common Stock

In other news, CEO Jennifer Jarrett bought 12,500 shares of Damora Therapeutics, Inc. Common Stock stock in a transaction dated Friday, September 25th. The shares were acquired at an average cost of $20.23 per share, with a total value of $252,875.00. Following the completion of the transaction, the chief executive officer owned 512,500 shares in the company, valued at approximately $10,367,875. This trade represents a 2.50% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.40% of the company's stock.

Institutional Investors Weigh In On Damora Therapeutics, Inc. Common Stock

A number of large investors have recently added to or reduced their stakes in DMRA. Arizona State Retirement System purchased a new stake in Damora Therapeutics, Inc. Common Stock during the 2nd quarter worth $260,000. Squarepoint Ops LLC purchased a new position in Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $303,000. Seven Fleet Capital Management LP purchased a new position in Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $7,398,000. Finally, Braidwell LP purchased a new position in Damora Therapeutics, Inc. Common Stock in the 2nd quarter valued at about $42,146,000. 14.20% of the stock is owned by institutional investors and hedge funds.

Damora Therapeutics, Inc. Common Stock Company Profile

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.